Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Cellebrite Q2 Miss Triggers...
Regulatory securities investigation

Cellebrite Q2 Miss Triggers Securities Investigation

Analysis based on 20 articles · First reported Aug 14, 2026 · Last updated Aug 20, 2026

Sentiment
-40
Attention
2
Articles
20
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Cellebrite's stock dropped over 30% following the Q2 earnings miss and guidance cut, reflecting investor disappointment and eroding market confidence. The securities investigation adds legal and reputational risk, potentially prolonging negative sentiment and increasing volatility for CLBT shares.

Software Legal Services
Event Summary

Cellebrite DI Ltd. (NASDAQ: CLBT) reported Q2 2026 financial results that missed revenue expectations, lowered full-year ARR and revenue guidance, and announced a CEO transition. The company reported ARR of $507.8 million, below the $510-$513 million range provided last quarter, and Q2 revenue of approximately $131.1 million, below analyst consensus. Management conceded they did not deliver the ARR and revenue performance they expected in the second quarter, pointing to longer sales cycles and a meaningful acceleration that did not materialize. The company slashed its projected ARR growth rate for fiscal 2026 to 14%-16%, down from the 18%-19% target reaffirmed just last quarter. The stock fell over 30% by midday trading. Levi & Korsinsky, a securities litigation firm, commenced an investigation into potential violations of federal securities laws, focusing on whether Cellebrite adequately disclosed risks inherent in its prior projections. The investigation also covers statements regarding ARR growth trajectory, revenue outlook, and expected expansion from Inseyets conversions. Shiven Ramji, recently appointed president, took over as CEO immediately.

Key Actions
90 Cellebrite missed revenue expectations
80 Levi & Korsinsky commenced investigation Cellebrite
60 Cellebrite announced CEO transition
60 Cellebrite appointed Shiven Ramji
Entities Involved
stock
Cellebrite
Cellebrite is the subject of the investigation. Its Q2 earnings miss and guidance cut triggered a sharp stock decline and legal scrutiny, damaging investor confidence and potentially leading to financial liabilities.
Importance 100.0 Sentiment -60.0
priv
Levi & Korsinsky
Levi & Korsinsky initiated the securities investigation, positioning itself to represent affected shareholders. The firm may benefit from contingency fees if a recovery is achieved.
Importance 80.0 Sentiment 20.0
per
David Barnea
David Barnea, as CFO, made the projections that are now under scrutiny. His statements are central to the investigation, and his credibility may be affected.
Importance 60.0 Sentiment -30.0
per
Shiven Ramji
Shiven Ramji was appointed CEO as part of the announced transition, taking over during a period of financial underperformance and legal investigation, which may affect his leadership tenure.
Importance 60.0 Sentiment -20.0
per
Joseph E. Levi
Joseph E. Levi is a partner at Levi & Korsinsky and a contact for the investigation, playing a key role in the legal process.
Importance 40.0 Sentiment 10.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.